Literature DB >> 21470541

Endopyelotomy still has an important role in the management of ureteropelvic junction obstruction.

Dinesh Samarasekera1, Ben H Chew.   

Abstract

Entities:  

Year:  2011        PMID： 21470541      PMCID： PMC3104430          DOI： 10.5489/cuaj.11032

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN： 1911-6470            Impact factor:   1.862


× No keyword cloud information.
  23 in total

1.  Intubated ureterotomy; experimental work and clinical results.

Authors:  D M DAVIS; G H STRONG; W M DRAKE
Journal:  J Urol       Date:  1948-05       Impact factor: 7.450

2.  Endopyelotomy versus open pyeloplasty: comparison in 88 patients.

Authors:  G S Karlin; G H Badlani; A D Smith
Journal:  J Urol       Date:  1988-09       Impact factor: 7.450

3.  Ureteroscopic pyelolysis for pelviureteric junction obstruction.

Authors:  J A Inglis; D A Tolley
Journal:  Br J Urol       Date:  1986-06

4.  Endopyelotomy for primary ureteropelvic junction obstruction: risk factors determine the success rate.

Authors:  H Danuser; D K Ackermann; D Böhlen; U E Studer
Journal:  J Urol       Date:  1998-01       Impact factor: 7.450

Review 5.  Open surgical exploration after failed endopyelotomy: a 12-year perspective.

Authors:  M Gupta; O L Tuncay; A D Smith
Journal:  J Urol       Date:  1997-05       Impact factor: 7.450

6.  Ureteropelvic junction obstruction: does CT angiography allow better selection of therapeutic modalities and better patient outcome?

Authors:  Danny Rabah; Douglas W Soderdahl; Paul D McAdams; Yasmeen K Knowles; Harlan L Vingan; Sarah C Shaves; Michael D Fabrizio
Journal:  J Endourol       Date:  2004-06       Impact factor: 2.942

7.  Role of multiphasic helical computed tomography in planning surgical treatment for pelvi-ureteric junction obstruction.

Authors:  Ahmed R El-Nahas; Mohamed Abou-El-Ghar; Ahmed M Shoma; Ibrahim Eraky; Mahmoud R El-Kenawy; Hamdy El-Kappany
Journal:  BJU Int       Date:  2004-09       Impact factor: 5.588

8.  Management of secondary ureteropelvic junction obstruction after failed primary laparoscopic pyeloplasty.

Authors:  Ioannis M Varkarakis; Sam B Bhayani; Mohamad E Allaf; Takeshi Inagaki; Albert M Ong; Louis R Kavoussi; Thomas W Jarrett
Journal:  J Urol       Date:  2004-07       Impact factor: 7.450

9.  Retrograde ureteroscopic holmium laser endopyelotomy in a selected population of patients with ureteropelvic junction obstruction.

Authors:  Nicolaj M Stilling; Helene Jung; Bettina Nørby; Susanne S Osther; Palle J S Osther
Journal:  Scand J Urol Nephrol       Date:  2009

10.  Single-center comparison of laparoscopic pyeloplasty, Acucise endopyelotomy, and open pyeloplasty.

Authors:  D Duane Baldwin; Jennifer A Dunbar; Nancy Wells; Elspeth M McDougall
Journal:  J Endourol       Date:  2003-04       Impact factor: 2.942
View more
  4 in total

1.  Comparison of Retrograde Balloon Dilatation and Laparoscopic Pyeloplasty for Treatment of Ureteropelvic Junction Obstruction: Results of a 2-Year Follow-Up.

Authors:  Ning Xu; Shao-Hao Chen; Xue-Yi Xue; Qing-Shui Zheng; Yong Wei; Tao Jiang; Xiao-Dong Li; Jin-Bei Huang; Hai Cai
Journal:  PLoS One       Date:  2016-03-28       Impact factor: 3.240

Review 2.  Management of ureteropelvic junction obstruction in adults.

Authors:  Fahd Khan; Kamran Ahmed; Nikiesha Lee; Ben Challacombe; Mohammed S Khan; Prokar Dasgupta
Journal:  Nat Rev Urol       Date:  2014-10-07       Impact factor: 14.432

3.  Transperitoneal mini-laparoscopic pyeloplasty and concomitant ureteroscopy-assisted pyelolithotomy for ureteropelvic junction obstruction complicated by renal caliceal stones.

Authors:  Zhi Chen; Peng Zhou; Zhong-Qing Yang; Yang Li; Yan-Cheng Luo; Yao He; Nan-Nan Li; Chao-Qun Xie; Chen Lai; Xiao-Long Fang; Xiang Chen
Journal:  PLoS One       Date:  2013-01-09       Impact factor: 3.240

4.  Surgical approaches for treatment of ureteropelvic junction obstruction - a systematic review and network meta-analysis.

Authors:  Annemarie Uhlig; Johannes Uhlig; Lutz Trojan; Marc Hinterthaner; Alexander von Hammerstein-Equord; Arne Strauss
Journal:  BMC Urol       Date:  2019-11-11       Impact factor: 2.264
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.